100 A new study has shed light on how glioblastoma, the most aggressive form of brain cancer, manages to evade the body’s immune system, offering fresh hope for innovative treatments. Published in the journal Critical Reviews in Oncology/Hematology, the research dives deep into the role of a molecule called IDO and the metabolism of tryptophan, an essential amino acid, in helping the tumour suppress immune responses both locally and across the body. This discovery could pave the way for therapies that turn the immune system back into a cancer-fighting force. Glioblastoma has long baffled scientists with its ability to resist standard treatments like surgery, radiotherapy, and chemotherapy. The tumour’s knack for dodging the immune system is a key reason for its deadly reputation. The study, led by Filippo Gagliardi and his team, reveals that IDO, an enzyme, plays a starring role in this evasion. By breaking down tryptophan, IDO creates a cascade of chemical byproducts that stifle immune cells, effectively putting the brakes on the body’s natural defences. This process not only happens within the tumour itself but also ripples out to influence immune responses far beyond the brain. The researchers conducted a sweeping review of existing studies, sifting through thousands of papers to pinpoint how tryptophan metabolism drives this immune suppression. They found that the tumour microenvironment, a bustling hub of cancer cells, immune cells, and supporting structures, becomes a hostile place for the body’s defenders. T-cells, which are crucial for attacking cancer, are particularly hard-hit, with their numbers dwindling and their activity curtailed. Meanwhile, other immune cells, like macrophages and microglia, are co-opted by the tumour to promote its growth rather than fight it. What makes this study stand out is its exploration of the systemic effects. The team discovered that changes in tryptophan metabolism can be detected in the blood, hinting at a way to monitor the disease’s progression without invasive procedures. Even more promising is the suggestion that targeting IDO and related enzymes could disrupt the tumour’s defences. Early experiments with inhibitors have shown they can shrink glioblastoma in lab models, sparking excitement about potential new drugs. These findings build on a growing understanding that cancer’s strength lies not just in its rapid growth, but in its ability to manipulate the body’s own systems. For patients facing this relentless disease, the implications are profound. Current treatments often buy time but rarely a cure, with most surviving less than 15 months after diagnosis. By cracking the code of glioblastoma’s immune evasion, scientists are edging closer to therapies that could bolster resilience against the cancer’s advance. The study calls for more research to refine these approaches, but the prospect of harnessing the immune system offers a glimmer of optimism in an otherwise grim landscape. As the battle against glioblastoma intensifies, this work underscores the power of unravelling the tumour’s tricks to unlock life-saving solutions.